Test Price
2,800 AED✅ Home Collection Available
SDHB Gene Pheochromocytoma Type 2 Genetic Test in UAE
Executive Summary & Core Metrics
Diagnostic Accuracy: 99.9% sensitivity via ISO-certified next-generation sequencing (NGS) for complete SDHB coding region analysis.
Premium Logistics: VIP mobile phlebotomy with temperature-controlled cold-chain collection available daily from 8 AM to 11 PM across all UAE emirates.
Clinical Guidance: Post-test genetic counseling session included to interpret results and plan personalized surveillance strategies.
Insurance Verification: Real-time coverage check via WhatsApp at +971 54 548 8731 prior to sample collection.
Test Overview & Methodology
The SDHB gene NGS test analyzes the entire coding region of the succinate dehydrogenase subunit B gene using next-generation sequencing to identify germline mutations responsible for hereditary pheochromocytoma/paraganglioma type 2. This advanced molecular assay delivers 99.9% diagnostic sensitivity, enabling precise risk stratification and personalized surveillance planning for patients and at-risk families across the UAE.
| Attribute | Our NGS Test | Sanger Sequencing Alternative |
|---|---|---|
| Gene Coverage | Full SDHB coding region, including exon-intron boundaries; detects point mutations, small indels, and large deletions/duplications | Limited to known mutational hotspots; may miss copy-number variations or deep intronic variants |
| Methodology | Next-generation sequencing with bioinformatic validation and orthogonal confirmation | Conventional Sanger sequencing with lower throughput and reduced sensitivity for mosaicism |
| Turnaround Time | 3–4 Weeks from sample receipt | 4–6 Weeks from sample receipt |
| Regulatory Compliance | DHA-licensed, UAE PDPL compliant, ISO-certified | Often lacks UAE-specific data privacy and informed consent protocols |
Physician Insight & Safety Protocols
“Genetic testing for SDHB mutations provides a molecular window into hereditary cancer risk—not a diagnosis of active disease. A positive result must be contextualized with clinical examination, family pedigree analysis, and biochemical screening. Our team translates complex genomic data into an actionable, compassionate surveillance plan for every patient.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Important Safety Advisory
Medication Caution
Do not discontinue any prescribed antihypertensive medications, alpha-blockers, or beta-blockers without consulting your treating physician. Genetic test results indicate susceptibility—they do not dictate immediate treatment changes. Any suspected catecholamine surge warrants urgent clinical evaluation.
Patient Eligibility & Contraindications
Exclusion Criteria
- Inability to provide informed consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability; minors require parental or guardian consent.
- Severely hemolyzed, clotted, or microbially contaminated peripheral blood samples.
- Insufficient DNA quantity or quality from provided specimen (minimum 200 ng required for NGS library preparation).
Emergency Red Flags
- Sudden severe headache, palpitations, diaphoresis, or hypertensive crisis—possible undiagnosed catecholamine-secreting tumor.
- Fainting, excessive bleeding, or signs of infection (redness, swelling, warmth) at the phlebotomy site.
Patient FAQ & Clinical Guidance
1. What is SDHB gene testing and why is it performed?
SDHB gene sequencing identifies germline mutations in the succinate dehydrogenase subunit B gene, which are associated with hereditary pheochromocytoma/paraganglioma type 2. This test enables early cancer surveillance, risk stratification for at-risk family members, and personalized management planning for patients with suspected hereditary paraganglioma syndromes.
2. How should I prepare for this genetic test?
No special dietary or medication preparation is required prior to sample collection. However, pre-test genetic counseling is strongly recommended to discuss implications of possible results, including the potential for incidental findings and familial implications.
3. Is home blood collection available for this test across the UAE?
Yes, we offer VIP mobile phlebotomy with temperature-controlled cold-chain collection services across all seven emirates. Our nursing team is available daily from 8 AM to 11 PM, ensuring convenient and sterile sample procurement in the comfort of your home.
4. What does a positive SDHB mutation result mean for my health?
A positive result indicates an increased lifetime risk for developing pheochromocytoma or paraganglioma, typically with a penetrance of 25–40% by age 60. It does not confirm active disease. Results must be interpreted alongside biochemical testing (plasma metanephrines) and imaging surveillance, guided by a clinical geneticist.
UAE Regulatory & Data Privacy Adherence
Legal Compliance Framework
This medical service strictly adheres to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted at rest and in transit, stored on UAE-based servers, and never shared with third parties without explicit written consent. Clinical safety and patient consent protocols comply with Federal Decree-Law No. 4 of 2016 on Medical Liability.
Facility Licensed by Dubai Health Authority (License No. 1143). Accredited under ISO 15189:2012 for medical laboratory quality and competence.
Clinical & Logistical Metadata
| Test Name | SDHB Gene Sequencing (NGS) for Hereditary Pheochromocytoma/Paraganglioma Type 2 |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks from Sample Receipt |
| Sample Type / Matrix | Whole Blood (Peripheral Blood) in EDTA Tube; Minimum 3 mL |
| Methodology Used | Next-Generation Sequencing (NGS) with Bioinformatic Variant Calling |
| ICD-10-CM Code | Z13.89 (Encounter for screening for other genetic disorders) |
| LOINC Code | 79254-6 (SDHB gene mutation analysis in Blood by NGS) |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE — DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians